All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EHA2023 abstracts: What’s hot in AML?
To help navigate the exciting content being presented at the EHA2023 Congress, the AML Hub Steering Committee have provided their recommendations of the top abstracts to look for.
FDA lifts clinical hold on phase I study of FHD-286 in patients with R/R AML or MDS
On June 1, 2023, the FDA lifted the clinical hold on the phase I dose escalation study of FHD-286, a highly potent, selective, allosteric and orally available...
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.